The Impact of Informational Intervention on HPV Vaccination Intention among Heterosexual Men
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethics and Registration
2.2. Study Design
2.3. Power Analysis
2.4. Sample Preparation
2.5. Participants
2.6. Intervention
HPV (Human Papillomavirus):HPV infections are very common. Nearly everyone will get HPV at some point in their lives. Currently, more than 42 million Americans are infected with HPV types that cause disease. About 13 million Americans, including teens, become infected each year. HPV is spread through intimate skin-to-skin contact. You can get HPV by having vaginal, anal, or oral sex with someone who has the virus, even if they do not have signs or symptoms. Most HPV infections (9 out of 10) will go away on their own within 2 years. But sometimes, HPV infections will last longer and can cause some varieties of cancer. Every year in the United States, HPV causes about 36,000 cases of cancer in men and women.Then, participants saw the following information about the HPV vaccine:HPV Vaccination Information:The HPV vaccine provides safe, effective, and long-lasting protection against cancers caused by HPV. The HPV vaccine can prevent over 90% of cancers caused by HPV. More than 135 million doses of the HPV vaccine have been distributed since they were licensed in 2006. Data continue to show the vaccines are safe and effective. People who get the first dose at or after 15 years of age need 3 doses of the HPV vaccine. The recommended three-dose schedule is to get the initial dose, then the second dose 1–2 months later, and finally the third dose 6 months after the initial dose.
2.7. Outcome Measure
2.8. Statistical Analysis
2.8.1. Intervention Effects on HPV Vaccine Intentions
2.8.2. Factors Associated with HPV Vaccination Intentions
2.8.3. Relationship Status and Sexual History
2.8.4. Attitudes, Perceived Norms, and Perceived Behavioral Control
3. Results
3.1. Sample Characteristics
3.2. Intervention Effects on HPV Vaccination Intentions
3.3. Sexual History and Relationship Status
3.4. Attitudes towards Vaccination
3.5. Agentic and Communal Values
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Category | Pre-Screening Question | Choices |
---|---|---|
HPV Vaccine History | Have you previously received at least one dose of the human papillomavirus (HPV) vaccine? | No, Yes, Unsure |
Are you currently scheduled to receive an HPV vaccination? | No, Yes, Unsure | |
General Demographics | What is your sex assigned at birth? | Male, Female, Prefer not to say |
What is your current gender identity? | Female, Male, Transgender Female, Transgender Male, Gender Variant/Non-conforming, Not listed ____, Prefer not to say | |
Which of the following best describes your sexual orientation? | Straight/Heterosexual, Homosexual, Bisexual, Asexual, Other, Not listed ___, Prefer not to say | |
What is your age? | 0–17, 18–26, 27–35, 35–50, 50+, prefer not to say | |
Others | Do you have a yeast sensitivity or allergy? | No, Yes, Prefer not to say |
Condition | Text |
---|---|
Both | HPV (Human Papillomavirus): HPV infections are very common. Nearly everyone will get HPV at some point in their lives. Currently, more than 42 million Americans are infected with HPV types that cause disease. About 13 million Americans, including teens, become infected each year. HPV is spread through intimate skin-to-skin contact. You can get HPV by having vaginal, anal, or oral sex with someone who has the virus, even if they do not have signs or symptoms. Most HPV infections (9 out of 10) will go away on their own within 2 years. But sometimes, HPV infections will last longer and can cause some varieties of cancer. Every year in the United States, HPV causes about 36,000 cases of cancer in men and women. HPV Vaccination Information: The HPV vaccine provides safe, effective, and long-lasting protection against cancers caused by HPV. The HPV vaccine can prevent over 90% of cancers caused by HPV. More than 135 million doses of the HPV vaccine have been distributed since they were licensed in 2006. Data continue to show the vaccines are safe and effective. People who get the first dose at or after 15 years of age need 3 doses of the HPV vaccine. The recommended three-dose schedule is to get the initial dose, then the second dose 1–2 months later, and finally the third dose 6 months after the initial dose. By getting the HPV vaccine, you could be protecting yourself from cancers like… Anal cancer: HPV is thought to cause 88.7% of male anus cancer in the United States. Oropharyngeal (Back of the throat) cancer: HPV is thought to cause 72.4% of male oropharyngeal cancers in the United States. Penile cancer: HPV is thought to cause 66.3% of penile cancers in the United States. According to data from 2015 to 2019, an estimated 47,199 new cases of human papillomavirus (HPV)-associated cancers occurred in the United States each year, including 21,022 among men. By getting the HPV vaccine, you could be protecting your female partner from cancers like… Anal cancer: HPV is thought to cause 92.5% of female anus cancers in the United States. Cervical cancer: HPV is thought to cause 90.6% of cervical cancers in the United States. Vaginal cancer: HPV is thought to cause 75.5% of vaginal cancers in the United States. Vulval cancer: HPV is thought to cause 68.8% of vulva cancers in the United States. Oropharyngeal (Back of the throat) cancer: HPV is thought to cause 63.3% of female oropharyngeal cancers in the United States. According to data from 2015 to 2019, an estimated 47,199 new cases of human papillomavirus (HPV)-associated cancers occurred in the United States each year, including 26,177 among women. [Protect yourself and your partner. Get vaccinated against HPV today.] |
Control | HPV (Human Papillomavirus): HPV infections are very common. Nearly everyone will get HPV at some point in their lives. Currently, more than 42 million Americans are infected with HPV types that cause disease. About 13 million Americans, including teens, become infected each year. HPV is spread through intimate skin-to-skin contact. You can get HPV by having vaginal, anal, or oral sex with someone who has the virus, even if they do not have signs or symptoms. Most HPV infections (9 out of 10) will go away on their own within 2 years. But sometimes, HPV infections will last longer and can cause some varieties of cancer. Every year in the United States, HPV causes about 36,000 cases of cancer in men and women. HPV Vaccination Information: The HPV vaccine provides safe, effective, and long-lasting protection against cancers caused by HPV. The HPV vaccine can prevent over 90% of cancers caused by HPV. More than 135 million doses of the HPV vaccine have been distributed since they were licensed in 2006. Data continue to show the vaccines are safe and effective. People who get the first dose at or after 15 years of age need 3 doses of the HPV vaccine. The recommended three-dose schedule is to get the initial dose, then the second dose 1–2 months later, and finally the third dose 6 months after the initial dose. [Get vaccinated against HPV today.] |
Other-oriented | HPV (Human Papillomavirus): HPV infections are very common. Nearly everyone will get HPV at some point in their lives. Currently, more than 42 million Americans are infected with HPV types that cause disease. About 13 million Americans, including teens, become infected each year. HPV is spread through intimate skin-to-skin contact. You can get HPV by having vaginal, anal, or oral sex with someone who has the virus, even if they do not have signs or symptoms. Most HPV infections (9 out of 10) will go away on their own within 2 years. But sometimes, HPV infections will last longer and can cause some varieties of cancer. Every year in the United States, HPV causes about 36,000 cases of cancer in men and women. HPV Vaccination Information: The HPV vaccine provides safe, effective, and long-lasting protection against cancers caused by HPV. The HPV vaccine can prevent over 90% of cancers caused by HPV. More than 135 million doses of the HPV vaccine have been distributed since they were licensed in 2006. Data continue to show the vaccines are safe and effective. People who get the first dose at or after 15 years of age need 3 doses of the HPV vaccine. The recommended three-dose schedule is to get the initial dose, then the second dose 1–2 months later, and finally the third dose 6 months after the initial dose. By getting the HPV vaccine, you could be protecting your female partner from cancers like… Anal cancer: HPV is thought to cause 92.5% of female anus cancers in the United States. Cervical cancer: HPV is thought to cause 90.6% of cervical cancers in the United States. Vaginal cancer: HPV is thought to cause 75.5% of vaginal cancers in the United States. Vulval cancer: HPV is thought to cause 68.8% of vulva cancers in the United States. Oropharyngeal (Back of the throat) cancer: HPV is thought to cause 63.3% of female oropharyngeal cancers in the United States. According to data from 2015 to 2019, an estimated 47,199 new cases of human papillomavirus (HPV)-associated cancers occurred in the United States each year, including 26,177 among women. [Protect your partner. Get vaccinated against HPV today.] |
Self-oriented | HPV (Human Papillomavirus): HPV infections are very common. Nearly everyone will get HPV at some point in their lives. Currently, more than 42 million Americans are infected with HPV types that cause disease. About 13 million Americans, including teens, become infected each year. HPV is spread through intimate skin-to-skin contact. You can get HPV by having vaginal, anal, or oral sex with someone who has the virus, even if they do not have signs or symptoms. Most HPV infections (9 out of 10) will go away on their own within 2 years. But sometimes, HPV infections will last longer and can cause some varieties of cancer. Every year in the United States, HPV causes about 36,000 cases of cancer in men and women. HPV Vaccination Information: The HPV vaccine provides safe, effective, and long-lasting protection against cancers caused by HPV. The HPV vaccine can prevent over 90% of cancers caused by HPV. More than 135 million doses of the HPV vaccine have been distributed since they were licensed in 2006. Data continue to show the vaccines are safe and effective. People who get the first dose at or after 15 years of age need 3 doses of the HPV vaccine. The recommended three-dose schedule is to get the initial dose, then the second dose 1–2 months later, and finally the third dose 6 months after the initial dose. By getting the HPV vaccine, you could be protecting yourself from cancers like… Anal cancer: HPV is thought to cause 88.7% of male anus cancer in the United States. Oropharyngeal (Back of the throat) cancer: HPV is thought to cause 72.4% of male oropharyngeal cancers in the United States. Penile cancer: HPV is thought to cause 66.3% of penile cancers in the United States. According to data from 2015 to 2019, an estimated 47,199 new cases of human papillomavirus (HPV)-associated cancers occurred in the United States each year, including 21,022 among men. [Protect yourself. Get vaccinated against HPV today.] |
Appendix B
Descriptive Statistics | p-Values for Overall Test and Planned Contrast | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Both | Control | Other | Self | ||||||||||||
Item Type | Item Text | Scale | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Overall Test | Control vs. Experimental | Both vs. Self | Self vs. Partner | |
Attitude | vaccine_ benefit | How beneficial do you think it is for you to get the HPV vaccine? | 0 (not at all beneficial) to 100 (extremely beneficial) | 65.07 | 28.96 | 63.35 | 28.01 | 62.88 | 29.47 | 61.21 | 30.20 | 0.03 | 0.85 | 0.09 | 0.83 |
vaccine_ risk | How risky do you think it is for you to get the HPV vaccine? | 0 (not at all risky) to 100 (extremely risky) Likert scale | 33.21 | 25.80 | 33.96 | 26.88 | 32.87 | 28.36 | 33.19 | 27.67 | 0.02 | 0.28 | 0.90 | 0.87 | |
vaccine_ worried | To what extent are you worried about getting the HPV vaccine? | 1 (not at all worried) to 5 (extremely worried) | 2.40 | 1.12 | 2.22 | 1.13 | 2.40 | 1.21 | 2.26 | 1.16 | 0.02 | 0.94 | 0.83 | 0.26 | |
HPV_ sideeffect | How serious do you think the possible side effects of the HPV vaccines are for you? | 1 (not at all serious) to 5 (extremely serious) | 2.47 | 1.13 | 2.58 | 1.26 | 2.41 | 1.18 | 2.41 | 1.21 | 0.00 | 0.09 | 0.60 | 0.41 | |
HPV_ healththreat | How serious of a threat do you believe the HPV vaccine is for your health? | 1 (not at all serious) to 5 (extremely serious) | 2.33 | 1.13 | 2.38 | 1.25 | 2.31 | 1.21 | 2.35 | 1.23 | 0.00 | 0.14 | 0.98 | 0.63 | |
HPV_ infectionthreat | How serious of a threat do you believe a HPV infection is for your health? | 1 (not at all serious) to 5 (extremely serious) | 3.22 | 1.28 | 3.02 | 1.17 | 2.99 | 1.27 | 3.15 | 1.14 | 0.00 | 0.65 | 0.43 | 0.49 | |
Social Norm | subnorm_ people | Most people who are important to me think that I should get vaccinated against HPV. | 1 (completely disagree) to 7 (completely agree) | 4.18 | 1.83 | 4.22 | 1.86 | 3.88 | 1.89 | 4.11 | 1.81 | 0.09 | 0.26 | 0.20 | 0.06 |
subnorm_ expectation | It is expected that I will get vaccinated against HPV. | 1 (completely disagree) to 7 (completely agree) | 4.28 | 1.76 | 4.10 | 1.88 | 4.04 | 1.94 | 3.91 | 1.82 | 0.10 | 0.55 | 0.06 | 0.63 | |
subnorm_ want | The people in my life whose opinions I value most would want me to get vaccinated against HPV. | 1 (completely disagree) to 7 (completely agree) | 4.40 | 1.82 | 4.44 | 1.83 | 4.29 | 2.01 | 4.15 | 1.78 | 0.07 | 0.41 | 0.14 | 0.88 | |
Perceived Behavioral Control | becontrol_ uptome | Whether I get the HPV vaccine or not is not entirely up to me. | 1 (strongly agree) to 7 (strongly disagree) | 4.28 | 2.24 | 4.05 | 2.25 | 4.35 | 2.27 | 4.16 | 2.25 | 0.93 | 0.47 | 0.62 | 0.91 |
becontrol_ control | Getting the HPV vaccine is beyond my control. | 1 (strongly agree) to 7 (strongly disagree) | 4.94 | 1.92 | 4.92 | 2.05 | 5.10 | 2.05 | 4.82 | 2.09 | 0.84 | 0.68 | 0.66 | 0.14 | |
becontrol_ confidence | I am confident that I can get the HPV vaccine. | 1 (strongly agree) to 7 (strongly disagree) | 3.50 | 1.93 | 3.42 | 1.98 | 3.40 | 2.15 | 3.41 | 1.89 | 0.89 | 0.88 | 0.57 | 0.94 | |
Trust | Infotrust | How much do you trust the information you read about the HPV vaccine? | 1 (do not trust at all) to 6 (completely trust) | 4.30 | 1.27 | 4.33 | 1.22 | 4.35 | 1.30 | 4.21 | 1.24 | 0.80 | 0.71 | 0.85 | 0.50 |
Vaxtrust_ safe | Overall, how much do you trust that the HPV vaccine will be safe for you? | 1 (do not trust at all) to 6 (completely trust) | 4.28 | 1.24 | 4.41 | 1.27 | 4.31 | 1.42 | 4.25 | 1.36 | 0.74 | 0.29 | 0.96 | 0.77 | |
Vaxtrust_ effective | Overall, how much do you trust that the HPV vaccine will be effective? | 1 (do not trust at all) to 6 (completely trust) | 4.38 | 1.27 | 4.36 | 1.33 | 4.42 | 1.29 | 4.37 | 1.33 | 0.98 | 0.80 | 0.87 | 0.71 |
Appendix C
References
- “Why Get the HPV Vaccine,” Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/hpv/parents/vaccine/six-reasons.html (accessed on 25 July 2023).
- STD Facts—Human papillomavirus (HPV). Available online: https://www.cdc.gov/std/hpv/stdfact-hpv.htm (accessed on 25 July 2023).
- Senkomago, V.; Henley, S.J.; Thomas, C.C.; Mix, J.M.; Markowitz, L.E.; Saraiya, M. Human Papillomavirus–Attributable Cancers—United States, 2012–2016. MMWR Morb. Mortal. Wkly. Rep. 2019, 68, 724–728. [Google Scholar] [CrossRef] [PubMed]
- Van Dyne, E.A.; Henley, S.J.; Saraiya, M.; Thomas, C.C.; Markowitz, L.E.; Benard, V.B. Trends in Human Papillomavirus-Associated Cancers—United States, 1999–2015. MMWR Morb. Mortal. Wkly. Rep. 2018, 67, 918–924. [Google Scholar] [CrossRef] [PubMed]
- Huh, W.K.; Joura, E.A.; Giuliano, A.R.; Iversen, O.-E.; De Andrade, R.P.; Ault, K.A.; Bartholomew, D.; Cestero, R.M.; Fedrizzi, E.N.; Hirschberg, A.L.; et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: A randomised, double-blind trial. Lancet 2017, 390, 2143–2159. [Google Scholar] [CrossRef]
- Kavanagh, K.; Pollock, K.G.; Cuschieri, K.; Palmer, T.; Cameron, R.L.; Watt, C.; Bhatia, R.; Moore, C.; Cubie, H.; Cruickshank, M.; et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: A 7-year cross-sectional study. Lancet Infect. Dis. 2017, 17, 1293–1302. [Google Scholar] [CrossRef] [PubMed]
- Steinbrook, R. The potential of human papillomavirus vaccines. N. Engl. J. Med. 2006, 354, 1109–1112. [Google Scholar] [CrossRef] [PubMed]
- Chaturvedi, A.K.; Graubard, B.I.; Broutian, T.; Pickard, R.K.L.; Tong, Z.-Y.; Xiao, W.; Kahle, L.; Gillison, M.L. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J. Clin. Oncol. 2018, 36, 262–267. [Google Scholar] [CrossRef]
- Meites, E.; Szilagyi, P.G.; Chesson, H.W.; Unger, E.R.; Romero, J.R.; Markowitz, L.E. Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. Am. J. Transplant. 2019, 19, 3202–3206. [Google Scholar] [CrossRef]
- Boersma, P.; Black, L.I. Human Papillomavirus Vaccination among Adults Aged 18–26, 2013–2018. NCHS Data Brief. 2020, 354, 1–8. [Google Scholar]
- Rodriguez, A.M.; Do, T.Q.N.; Goodman, M.; Schmeler, K.M.; Kaul, S.; Kuo, Y.-F. Human Papillomavirus Vaccine Interventions in the U.S.: A Systematic Review and Meta-analysis. Am. J. Prev. Med. 2019, 56, 591–602. [Google Scholar] [CrossRef]
- Mavundza, E.J.; Iwu-Jaja, C.J.; Wiyeh, A.B.; Gausi, B.; Abdullahi, L.H.; Halle-Ekane, G.; Wiysonge, C.S. A Systematic Review of Interventions to Improve HPV Vaccination Coverage. Vaccines 2021, 9, 687. [Google Scholar] [CrossRef]
- Bonafide, K.E.; Vanable, P.A. Male Human Papillomavirus Vaccine Acceptance Is Enhanced by a Brief Intervention that Emphasizes Both Male-Specific Vaccine Benefits and Altruistic Motives. Sex. Transm. Dis. 2015, 42, 76–80. [Google Scholar] [CrossRef]
- Gerend, M.A.; Barley, J. Human papillomavirus vaccine acceptability among young adult men. Sex. Transm. Dis. 2009, 36, 58–62. [Google Scholar] [CrossRef]
- DiClemente, R.J.; Crosby, R.A.; Salazar, L.F.; Nash, R.; Younge, S. Is male intent to be vaccinated against HPV a function of the promotion message? Int. J. STD AIDS 2011, 22, 332–334. [Google Scholar] [CrossRef] [PubMed]
- Suh, E.J.; Moskowitz, D.S.; Fournier, M.A.; Zuroff, D.C. Gender and relationships: Influences on agentic and communal behaviors. Pers. Relatsh. 2004, 11, 41–60. [Google Scholar] [CrossRef]
- “Gender and Health,” World Health Organization. Available online: https://www.who.int/health-topics/gender (accessed on 25 July 2023).
- Evans, J.; Frank, B.; Oliffe, J.L.; Gregory, D. Health, illness, men and masculinities (HIMM): A theoretical framework for understanding men and their health. J. Mens Health 2011, 8, 7–15. [Google Scholar] [CrossRef]
- Zhang, S. The Effect of Messaging Intervention on Male HPV Vaccination. March 2023. Available online: https://osf.io/fd6mh/ (accessed on 2 August 2023).
- State Vaccine Requirements for College Entry. Available online: https://www.ncsl.org/health/state-vaccine-requirements-for-college-entry (accessed on 13 August 2023).
- Marshall, S.; Moore, A.C.; Fleming, A.; Sahm, L.J. A Video-Based Behavioral Intervention Associated with Improved HPV Knowledge and Intention to Vaccinate. Vaccines 2022, 10, 562. [Google Scholar] [CrossRef] [PubMed]
- Saraiya, M.; Unger, E.R.; Thompson, T.D.; Lynch, C.F.; Hernandez, B.Y.; Lyu, C.W.; Steinau, M.; Watson, M.; Wilkinson, E.J.; Hopenhayn, C.; et al. US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. JNCI J. Natl. Cancer Inst. 2015, 107, djv086. [Google Scholar] [CrossRef]
- Rosenthal, S.L.; Weiss, T.W.; Zimet, G.D.; Ma, L.; Good, M.B.; Vichnin, M.D. Predictors of HPV vaccine uptake among women aged 19–26: Importance of a physician’s recommendation. Vaccine 2011, 29, 890–895. [Google Scholar] [CrossRef]
- Trapnell, P.; Paulhus, D. Agentic and Communal Values: Their Scope and Measurement. J. Pers. Assess. 2012, 94, 39–52. [Google Scholar] [CrossRef]
- Baron, R.M.; Kenny, D.A. The Moderator-Mediator Variable Distinction in Social Psychological Research: Conceptual, Strategic, and Statistical Considerations. J. Personal. Soc. Psychol. 1986, 51, 1173–1182. [Google Scholar] [CrossRef]
- Kim, T.; John, L.; Barasz, K.; Norton, M. Calculators For Women: When Identity Appeals Provoke Backlash. ACR N. Am. Adv. 2019, 47, 254–258. Available online: https://www.acrwebsite.org/volumes/2550887/volumes/v47/NA-47 (accessed on 27 July 2023).
- Kim, T.; Barasz, K.; John, L.K.; Norton, M.I. Calculators for Women: When Identity-Based Appeals Alienate Consumers. J. Assoc. Consum. Res. 2023, 8, 72–82. [Google Scholar] [CrossRef]
- Godin, G.; Kok, G. The theory of planned behavior: A review of its applications to health-related behaviors. Am. J. Health Promot. 1996, 11, 87–98. [Google Scholar] [CrossRef] [PubMed]
Condition | n | Content | Reference | Word Count |
---|---|---|---|---|
Self | 145 | HPV-associated male diseases plus HPV general infection and vaccine information. “Protect yourself. Get vaccinated against HPV today” | CDC [1], Saraiya et al., 2015 [22] | 325 |
Partner | 144 | HPV-associated female diseases plus HPV general infection and vaccine information. “Protect your partner. Get vaccinated against HPV today” | CDC [1], Saraiya et al., 2015 [22] | 358 |
Both | 141 | HPV-associated male and female diseases plus HPV general infection and vaccine information. “Protect yourself and your partner. Get vaccinated against HPV today” | CDC [1], Saraiya et al., 2015 [22] | 467 |
Control | 153 | HPV general infection and vaccine information. “Get vaccinated against HPV today” | CDC [1] | 231 |
Baseline Characteristics | Both | Partner-Oriented | Self-Oriented | Control | ||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |
Gender | ||||||||
Male | 141 | 100 | 144 | 100 | 145 | 100 | 153 | 100 |
Age | ||||||||
18–26 | 141 | 100 | 144 | 100 | 145 | 100 | 153 | 100 |
Ethnicity | ||||||||
White | 71 | 50 | 71 | 49 | 75 | 52 | 76 | 50 |
Black or African American | 36 | 26 | 41 | 28 | 36 | 25 | 41 | 27 |
Hispanic | 13 | 9 | 13 | 9 | 16 | 11 | 15 | 10 |
American Indian or Alaska Native | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
Asian | 18 | 13 | 13 | 9 | 13 | 9 | 19 | 12 |
Native Hawaiian or Pacific Islander | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 |
Others | 3 | 2 | 4 | 3 | 2 | 1 | 1 | 1 |
Education | ||||||||
High School or Less | 5 | 4 | 8 | 6 | 8 | 6 | 6 | 4 |
High School Graduate | 72 | 51 | 77 | 53 | 87 | 60 | 83 | 54 |
Associate’s Degree | 22 | 16 | 17 | 12 | 11 | 8 | 16 | 10 |
Bachelor’s Degree | 38 | 27 | 33 | 23 | 33 | 23 | 37 | 24 |
Master’s or Professional Degree | 2 | 1 | 8 | 6 | 5 | 3 | 10 | 7 |
Doctorate Degree | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Occupation | ||||||||
Full-time | 67 | 48 | 57 | 40 | 67 | 46 | 75 | 49 |
Part-time | 25 | 18 | 22 | 15 | 30 | 21 | 24 | 16 |
Start New Job in Next Month | 0 | 0 | 1 | 1 | 3 | 2 | 3 | 2 |
Unemployed | 22 | 16 | 30 | 21 | 20 | 14 | 14 | 9 |
Not Gainfully Employed | 0 | 0 | 2 | 1 | 2 | 1 | 2 | 1 |
Student | 25 | 18 | 27 | 19 | 21 | 14 | 31 | 20 |
Others | 2 | 1 | 5 | 3 | 2 | 1 | 4 | 3 |
Income | ||||||||
Less than USD 9999 | 16 | 11 | 18 | 13 | 20 | 14 | 16 | 10 |
USD 10,000–49,999 | 37 | 26 | 59 | 41 | 46 | 32 | 54 | 35 |
USD 50,000–99,999 | 61 | 43 | 46 | 32 | 55 | 38 | 42 | 27 |
USD 100,000–149,999 | 18 | 13 | 16 | 11 | 18 | 12 | 22 | 14 |
USD 150,000 or more | 9 | 6 | 5 | 3 | 6 | 4 | 19 | 12 |
Sex History | ||||||||
Yes | 97 | 69 | 94 | 65 | 95 | 66 | 106 | 69 |
No | 36 | 26 | 49 | 34 | 42 | 29 | 38 | 25 |
Prefer Not to Say | 8 | 6 | 1 | 1 | 8 | 6 | 9 | 6 |
Sexually Active | ||||||||
Yes | 81 | 57 | 75 | 52 | 79 | 54 | 85 | 56 |
No | 54 | 38 | 66 | 46 | 57 | 39 | 62 | 41 |
Prefer Not to Say | 6 | 4 | 3 | 2 | 9 | 6 | 6 | 4 |
Relationship Status | ||||||||
Single | 80 | 57 | 95 | 66 | 91 | 63 | 90 | 59 |
In Relationship | 36 | 26 | 27 | 19 | 40 | 28 | 38 | 25 |
Recently Ended a Relationship | 2 | 1 | 3 | 2 | 1 | 1 | 0 | 0 |
Dating | 6 | 4 | 4 | 3 | 3 | 2 | 7 | 5 |
Engaged | 3 | 2 | 3 | 2 | 1 | 1 | 5 | 3 |
Married | 13 | 9 | 11 | 8 | 9 | 6 | 11 | 7 |
Prefer Not to Say | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhang, S.; Grant, L.H.; Geipel, J.; Cui, Z.; Keysar, B. The Impact of Informational Intervention on HPV Vaccination Intention among Heterosexual Men. Vaccines 2023, 11, 1653. https://doi.org/10.3390/vaccines11111653
Zhang S, Grant LH, Geipel J, Cui Z, Keysar B. The Impact of Informational Intervention on HPV Vaccination Intention among Heterosexual Men. Vaccines. 2023; 11(11):1653. https://doi.org/10.3390/vaccines11111653
Chicago/Turabian StyleZhang, Songyang, Leigh H. Grant, Janet Geipel, Zhihan Cui, and Boaz Keysar. 2023. "The Impact of Informational Intervention on HPV Vaccination Intention among Heterosexual Men" Vaccines 11, no. 11: 1653. https://doi.org/10.3390/vaccines11111653